{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:04:48Z","timestamp":1793505888418,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T00:00:00Z","timestamp":1463616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","award":["NCT01288027"],"award-info":[{"award-number":["NCT01288027"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ymgme.2016.05.013","type":"journal-article","created":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T08:58:50Z","timestamp":1463821130000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study"],"prefix":"10.1016","volume":"119","author":[{"given":"Ans","family":"van der Ploeg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre G.","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert-Yves","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Kissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Wenninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pestronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren D.M.","family":"Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Boentert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Wens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Shafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Bjartmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Thurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.05.013_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1212\/WNL.23.1.95","article-title":"The spectrum and diagnosis of acid maltase deficiency","volume":"23","author":"Engel","year":"1973","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0015","series-title":"OMMBD: The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2014"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0020","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0025","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.clinbiochem.2011.09.010","article-title":"The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States","volume":"44","author":"Adam","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0035","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"ACMG","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0050","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","article-title":"Late-onset Pompe disease primarily affects quality of life in physical health domains","volume":"63","author":"Hagemans","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0055","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","article-title":"Disease severity in children and adults with Pompe disease related to age and disease duration","volume":"64","author":"Hagemans","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0060","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.55.8.1122","article-title":"Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation","volume":"55","author":"Laforet","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2008.07.013","article-title":"Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities","volume":"275","author":"van der Beek","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"Gungor","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"Gungor","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/01.wnl.0000198776.53007.2c","article-title":"Course of disability and respiratory function in untreated late-onset Pompe disease","volume":"66","author":"Hagemans","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0090","series-title":"Lumizyme\u00ae (Alglucosidase Alfa) for Injection, for Intravenous Use. [Prescribing Information]","year":"2009"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0095","series-title":"Myozyme\u00ae (Alglucosidase Alfa) Injectable for Intravenous Infusion. [Prescribing Information]","year":"2009"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/14750708.4.3.271","article-title":"Alglucosidase alfa: first available treatment for Pompe disease","volume":"4","author":"Nicolino","year":"2007","journal-title":"Therapy"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0120","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0125","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0130","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0135","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4years","volume":"259","author":"Angelini","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0140","first-page":"85","article-title":"Familial adult-onset Pompe disease associated with unusual clinical and histological features","volume":"32","author":"Maggi","year":"2013","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0145","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.nmd.2014.06.254","article-title":"Late-onset Pompe disease: histopathological, biochemical and clinical assessment before and after ERT","volume":"24","author":"Sciacco","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","article-title":"Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease","volume":"18","author":"van Capelle","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0160","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/002215540505300108","article-title":"High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology","volume":"53","author":"Lynch","year":"2005","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0165","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jmri.24613","article-title":"Validation of a generic approach to muscle water T2 determination at 3T in fat-infiltrated skeletal muscle","volume":"41","author":"Azzabou","year":"2015","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ymgme.2016.05.013_bb0170","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.nmd.2011.06.748","article-title":"Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns","volume":"21","author":"Carlier","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0175","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0180","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2990.2007.00839.x","article-title":"Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited","volume":"33","author":"Schoser","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0185","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mus.10381","article-title":"Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy","volume":"27","author":"Winkel","year":"2003","journal-title":"Muscle Nerve"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2016.05.013_bb0190","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/j.nmd.2012.05.011","article-title":"Trunk muscle involvement in late-onset Pompe disease: study of thirty patients","volume":"22","author":"Alejaldre","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0195","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","article-title":"Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy","volume":"101","author":"Raben","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0200","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10545-015-9825-9","article-title":"Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients","volume":"38","author":"Carlier","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2016.05.013_bb0210","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10545-010-9204-5","article-title":"Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response","volume":"33","author":"Ravaglia","year":"2010","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T19:51:58Z","timestamp":1718567518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216300889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":42,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1096719216300889"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.013","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}